<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04442126</url>
  </required_header>
  <id_info>
    <org_study_id>NB-ND021 (NM21-1480)-101</org_study_id>
    <secondary_id>2020-0355</secondary_id>
    <nct_id>NCT04442126</nct_id>
  </id_info>
  <brief_title>A Study of NM21-1480 in Adult Patients With Advanced Solid Tumors</brief_title>
  <official_title>A Phase 1/2 Study of NM21-1480 (Anti-PDL-1/Anti-4-1BB/Anti-HSA Tri-Specific Antibody) in Adult Patients With Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Numab Therapeutics AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Numab Therapeutics AG</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a first-in-human, open-label, multi-center, Phase 1/2, dose-escalation study with&#xD;
      expansion cohorts to evaluate NM21-1480 for safety and immunogenicity, to determine the&#xD;
      maximal tolerated dose and recommended Phase 2 dose, define the pharmacokinetics, to explore&#xD;
      the pharmacodynamics, and to obtain preliminary evidence of the clinical activity in adult&#xD;
      patients with selected advanced solid tumors.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 19, 2020</start_date>
  <completion_date type="Anticipated">June 6, 2023</completion_date>
  <primary_completion_date type="Anticipated">January 7, 2023</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with treatment-related adverse events as assessed by CTCAE v5.0</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Frequency and severity of adverse events</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Tolerated Dose (MTD) of NM21-1480</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>To determine the MTD of NM21-1480</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Determination of Phase 2 dose of NM21-1480</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>To determine the recommended Phase 2 dose of NM21-1480 for Part B of the study</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">147</enrollment>
  <condition>Advanced Solid Tumor</condition>
  <condition>Non-small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>NM21-1480 Treatment arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>NM21-1480</intervention_name>
    <description>Trispecific anti-PD-L1/anti-4-1BB/anti-Human Serum Albumin (HSA) single-chain Fv fusion protein</description>
    <arm_group_label>NM21-1480 Treatment arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Part A&#xD;
&#xD;
          -  Patients with any previously treated solid tumor-type other than hepatocellular&#xD;
             carcinoma or intrahepatic cholangiocarcinoma that is advanced, or recurrent and&#xD;
             progressing since last anti-tumor therapy, and for which no alternative, standard&#xD;
             therapy exists.&#xD;
&#xD;
          -  Prior chemotherapy, radiation therapy or immunotherapy must have been completed at&#xD;
             least 4 weeks prior to the administration of the first dose of study drug, and patient&#xD;
             has recovered&#xD;
&#xD;
        Part B:&#xD;
&#xD;
          -  Patients with Non-small Cell Lung Cancer (NSCLC) or other protocol-specified solid&#xD;
             tumors with locally advanced or metastatic, non-resectable disease, which has&#xD;
             progressed despite treatment with first-line standard-of-care treatment, or first- and&#xD;
             second-line treatment, dependent on expansion cohort.&#xD;
&#xD;
          -  Prior therapy must have been completed 2-4 weeks prior to the administration of the&#xD;
             first dose of study drug as specified per protocol according to type of prior therapy.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient previously had known immediate or delayed hypersensitivity reaction or&#xD;
             idiosyncrasy to the excipients&#xD;
&#xD;
          -  Part A: Treatment with any PD-1, or Cytotoxic T-Lymphocyte Associated Protein (CTLA)-4&#xD;
             directed antibody, or with any other immunotherapy within 4 weeks prior to initiation&#xD;
             of the study drug.&#xD;
&#xD;
          -  Part A: Use of other biological investigational drugs (drugs not marketed for any&#xD;
             indication), including use of investigational drugs targeting CD137/4-1BB within at&#xD;
             least 5 half-lives (or within 8 weeks, whatever is longer) prior to the administration&#xD;
             of the first dose of study drug.&#xD;
&#xD;
          -  Part B: As defined per protocol for each expansion cohort, has not been treated with&#xD;
             specified first/second-line standard-of-care therapies biological drugs (marketed or&#xD;
             investigational) for treatment of the current cancer, or has not adequately recovered&#xD;
             from AEs that occurred with prior therapy.&#xD;
&#xD;
          -  Patient has an active autoimmune disease or a documented history of autoimmune&#xD;
             disease.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Peter Lichtlen, MD, PhD, BBA</last_name>
    <phone>+41-44-533-22-92</phone>
    <email>clinicaltrials@numab.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>UPMC Hillman Cancer Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sarah Brodeur, BS</last_name>
      <phone>412-623-2944</phone>
      <email>brodeurs@upmc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Cancer Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melissa L. Johnson, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The University Of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David S Hong, MD</last_name>
      <phone>713-563-7930</phone>
      <email>dshong@mdanderson.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>James Chih-Hsin Yang, MD, PhD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Taiwan</country>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>June 18, 2020</study_first_submitted>
  <study_first_submitted_qc>June 19, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 22, 2020</study_first_posted>
  <last_update_submitted>May 18, 2021</last_update_submitted>
  <last_update_submitted_qc>May 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Carcinoma</keyword>
  <keyword>Neoplasms</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

